Primary and metastatic peritoneal surface malignancies
Peritoneal surface malignancies comprise a heterogeneous group of primary tumours,
including peritoneal mesothelioma, and peritoneal metastases of other tumours, including …
including peritoneal mesothelioma, and peritoneal metastases of other tumours, including …
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Mutation-induced activation of WNT–β-catenin signalling is a frequent driver event in human
cancer. Sustained WNT–β-catenin pathway activation endows cancer cells with sustained …
cancer. Sustained WNT–β-catenin pathway activation endows cancer cells with sustained …
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a …
F Quénet, D Elias, L Roca, D Goéré, L Ghouti… - The Lancet …, 2021 - thelancet.com
Background The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to
cytoreductive surgery has been associated with encouraging survival results in some …
cytoreductive surgery has been associated with encouraging survival results in some …
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
M Alyami, M Hübner, F Grass, N Bakrin… - The Lancet …, 2019 - thelancet.com
Pressurised intraperitoneal aerosol chemotherapy (PIPAC) was introduced as a new
treatment for patients with peritoneal metastases in November, 2011. Reports of its …
treatment for patients with peritoneal metastases in November, 2011. Reports of its …
Molecular characterization of colorectal cancer related peritoneal metastatic disease
KJ Lenos, S Bach, L Ferreira Moreno… - Nature …, 2022 - nature.com
A significant proportion of colorectal cancer (CRC) patients develop peritoneal metastases
(PM) in the course of their disease. PMs are associated with a poor quality of life, significant …
(PM) in the course of their disease. PMs are associated with a poor quality of life, significant …
Thermosensitive exosome–liposome hybrid nanoparticle‐mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer
Q Lv, L Cheng, Y Lu, X Zhang, Y Wang… - Advanced …, 2020 - Wiley Online Library
Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To
improve treatment of this disease, a recently developed hyperthermic intraperitoneal …
improve treatment of this disease, a recently developed hyperthermic intraperitoneal …
Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial
A Arjona-Sánchez, E Espinosa-Redondo… - JAMA …, 2023 - jamanetwork.com
Importance Peritoneal metastasis in patients with locally advanced colon cancer (T4 stage)
is estimated to recur at a rate of approximately 25% at 3 years from surgical resection and is …
is estimated to recur at a rate of approximately 25% at 3 years from surgical resection and is …
[HTML][HTML] Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial
LM Howells, COO Iwuji, GRB Irving, S Barber… - The Journal of …, 2019 - Elsevier
Background Curcumin is the main active ingredient of the spice turmeric, investigated
extensively for putative anticancer properties. Objectives This phase IIa open-labelled …
extensively for putative anticancer properties. Objectives This phase IIa open-labelled …
Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy
Purpose: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited
treatment options and the lowest colorectal cancer survival rates. We aimed to determine …
treatment options and the lowest colorectal cancer survival rates. We aimed to determine …
of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?
The TNM classification of malignant tumours is a mainstay tool in clinical practice and
research for prognostic assessment of patients, treatment allocation and trial enrolment, as …
research for prognostic assessment of patients, treatment allocation and trial enrolment, as …